Sparks commentary

Healthcare

Sparks

FDA approves Vertex’s (NASDAQ: VRTX) pain drug
Published by Arron Aatkar, PhD

The US FDA has approved Vertex’s suzetrigine, now called Journavx, for the treatment of adults with moderate-to-severe acute pain. Vertex has spent many decades in the challenging field of pain management and the approval of  Journavx represents a significant milestone in public health, especially following the opioid epidemic in the US.

 

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free